Navigation Links
Osteologix Announces Completion of Corporate Consolidation
Date:8/5/2011

e active component of which significantly improves bone mineral density and reduces fracture risk.  NB S101 has demonstrated significant beneficial effects in a Phase 2 clinical trial by reducing bone resorption and increasing strong bone formation. This dual action on bone- a significant medical need not served by current therapies in the U.S.- suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis.  Importantly, NB S101 appears to help build bone in a manner similar to the body's own metabolic processes by rebalancing bone metabolism in a way that favors strong bone formation.  Key patents for NB S101 have been issued in the United States, Europe and Japan, providing protection to at least 2024.

About Osteologix
Osteologix is a specialty pharmaceutical company focused on the development of innovative therapies for the treatment and prevention of diseases of bone and joint tissues. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. In November 2007, Osteologix completed a Phase II clinical trial of NB S101 that demonstrated the ability of NB S101 to reduce markers of bone resorption and increase bone mineral density. In July, 2010 Osteologix granted the Servier Research Group an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) and other strontium salts covered by Osteologix's patent rights to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. For more information please visit http://www.osteologix.com.

Safe Harbor Statement:
Statements in this press release are not strictly historical, including statements about the corporate consolidation, operating on a positive cash flow basis, the payment and timing of any potential dividends, potential paymen
'/>"/>

SOURCE Osteologix Holdings, PLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... ear could improve the health of your heart, researchers ... Leeds used a standard TENS machine like those designed ... the tragus, the small raised flap at the front ... canal. , The stimulation changed the influence of the ... signals that can drive failing hearts too hard. , ...
(Date:8/19/2014)... Piscataway, NJ (PRWEB) August 20, 2014 ... engineering and regenerative medicine is an inadequate vascular ... engineered constructs and decellularized tissues is critical for ... Researchers have attempted to mitigate deficiencies in vascularization ... including adding scaffold bioactivity, optimizing scaffold design and ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... Robin Williams’ passing is a sad reminder ... individual. Symptoms range from slowness of voluntary movements ... severe depression. Parkinson’s disease progressively gets worse over ... neurons of the brain. As these patients struggle ... progressively gets worse, they look for options. ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... , , BRISBANE, Calif., Sept. 17 ... it will be collaborating with National Jewish Health(R)( )investigators in ... may play a role in idiopathic pulmonary fibrosis (IPF). InterMune ... from patients who participated in the Company,s Phase 3 clinical trials ...
... BETHESDA, Md., Sept. 16 American Capital Ltd. ... 15, it completed the sale of its portfolio company Axygen ... Inc., to Corning Incorporated for approximately $400 million. The ... fee income, from the equity invested by American Capital,s affiliated ...
... SAN MARINO, Calif., Sept. 16 Dr. M. Karen ... (Pink Sheets: VRAL), will address the 11th Annual SoCalBio Investor ... Custom Peptides on Chronic Inflammation," will take place mid-morning on ... The Loews Santa Monica Beach Hotel in Santa Monica, California. ...
Cached Biology Technology:InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 2InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 2American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 3American Capital Receives $182 Million In Proceeds From Sale of Axygen Bioscience 4Viral Genetics' Lead Scientist Dr. M. Karen Newell Will Present at 11th Annual SoCalBio Investor and Partnership Conference 2
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
(Date:8/20/2014)... life can persist in a cold, dark world. A ... that examined waters and sediments from a shallow lake ... extreme environment supports microbial ecosystems. , The National ... has implications for life in other extreme environments, both ... are published in the current edition of the science ...
Breaking Biology News(10 mins):Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Nature journal Leukemia suggests blocking part of ... leukemia resist treatment can increase the effectiveness of chemotherapy ... Medical Center report that their experimental combination treatment strategy ... was particularly effective at stopping a stubborn leukemia ...
... August 8, 2013 Research and ... addition of the "Fingerprint Biometrics - Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This report ... in US$ Thousands by the following Product ...
... world full of hungry predators, prey animals must be constantly ... challenge when it comes to defending themselves. "One of ... they can,t run away," says John Orrock, a zoology professor ... necessarily hide, so what can you do? Some plants make ...
Cached Biology News:Study suggests way to fight therapy resistant leukemia by blocking DNA repair 2Study suggests way to fight therapy resistant leukemia by blocking DNA repair 3Fingerprint Biometrics: Automated FIS, and Non-AFIS - Global Strategic Business Report - 2013 2Eavesdropping plants prepare to be attacked 2
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... KLH-conjugated, synthetic peptide corresponding ... of mouse p19ARF. The ... acids 62-75. Clone 5-C3-1. ... by immunoblot. Stability ...
Request Info...
Biology Products: